Previous 10 | Next 10 |
2024-05-09 08:15:00 ET Summary Teva Pharmaceutical stock has been trending higher since October 2023, closing at nearly $16.00. The company reported strong first-quarter results, with increased revenue and growth in key metrics. Teva has a positive business outlook for 2024, w...
2024-05-08 09:10:25 ET Summary Organon released its Q1 2024 results on May 2, and the company's stock has nearly doubled since its low just five months ago. In this update, I take a look at the pharmaceutical and biosimilars company's Q1 earnings report and determine whether the m...
2024-05-08 04:06:42 ET More on Organon Four Reasons Why Organon Stock Is A Good Buy Organon & Co. (OGN) Q1 2024 Earnings Call Transcript Organon Stock Is Still Worth A Look Organon Non-GAAP EPS of $1.22 beats by $0.29, revenue of $1.62B beats by $60M ...
Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with...
2024-05-07 12:43:50 ET Summary OGN has underperformed its healthcare peers and the benchmark over the past year, but this could change going forward. The company's dominant women's health product- Nexplanon is looking at double-digit growth in sales this year, even as market loss ...
2024-05-07 08:21:25 ET More on Organon Organon Stock Is Still Worth A Look Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last Read the full article on Seeking Alpha For further details see: Organon plans to offer $1B in senior notes
Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with...
2024-05-02 11:53:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Organon (NYSE: OGN ) just reported results for the first quarter of 2024. Organon reported earnings per share of $1.22. This was above the analyst estimate for EPS of 93 c...
2024-05-02 11:09:10 ET Organon & Co. (OGN) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Confer...
2024-05-02 08:11:46 ET More on Organon Organon Stock Is Still Worth A Look Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last Organon & Co. (OGN) Q4 2023 Earnings Call Transcript Organon Non-GAAP EPS of $1.22 beats by $0.29, revenue ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...